Background High dose potent statin is known to be effective in reducing major adverse cardiovascular events (MACE) among patients (pts) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DESs). We evaluated whether the rosuvastatin, so called superstatin can be associated with better long-term clinical outcomes compared with other potent statins in Asian population. Methods The study population consisted of 998 consecutive patients (pts) undergoing PCI with DESs from November 2005 to June 2008. Angiographic outcomes at 6 months and cumulative clinical outcomes up to 2 years were compared between rosuvastatin group (n= 469 pts, 47.0%) and other statin group (n=528 pts, 58.0%) including atorvastatin (n=280 pts) and pitavastatin (n=248 pts). Results Both groups had similar baseline clinical and procedural characteristics. Six-month angiographic outcomes showed that rosuvastatin group had lower mean restenosis percent (%) but had similar incidence of binary stenosis and late loss as compared with the other statin group. Major clinical outcomes were similar between the two groups up to 2 years including cardiac death, Q wave MI, repeat PCI and TVR MACE (Table). Conclusions: Although rosuvastatin administration was associated with lower restenosis percent (%), this angiographic benefit was not translated into better clinical outcomes compared with other potent statin group up to 2 years.